DropGenie

DropGenie aims to accelerate the pace of discovery in the biotechnology industry with its innovative solutions. The company, founded in 2018 in the United States, focuses on supercharging automation and reducing the time to answer through miniaturization and parallelization. Their first product offering, an automation-compatible microfluidics chip, enables non-viral transfection in precious cells. This breakthrough technology opens the door to whole genome arrayed CRISPR screening at single donor resolution. The company recently received a non-equity assistance investment from OneRise at 28th February 2023. DropGenie's exciting and pioneering endeavors in the biotechnology sector are attracting attention and investment interest, positioning it as a promising venture for potential investors looking to tap into the advancements within the industry.